Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer (RITCOLON)

Nantes University Hospital (NUH)

Status and phase: Terminated; Phase 2; Phase 1

Conditions: Metastatic Colorectal Cancer

Treatments: Drug: 90-Y-IMP-288; Drug: 111-In-IMP-288; Drug: Antibody TF2

Study type: Interventional

Funder types: Other

Identifiers

NCT02300922

RC14_0003

Details and patient eligibility

About

Phase I/II, Open-labeled, Prospective, Multi-center study of a Pretargeted Radioimmunotherapy in metastatic colorectal cancer with ractionated injections of TF2 plus 90Y-IMP288 (RITCOLON).

Full description

This study investigates a pretargeted radioimmunotherapy (pRAIT) with the anti-carcinoembryonic antigen (CEA) TF2 bispecific monoclonal antibody (BsMAb) and the 90Y-IMP288 radio-labeled peptide.

TF2 will be given once a week for 3 successive weeks at 75 mg/m2 per dose. IMP288 will be given 3 times, 1 day after each TF2 injection. IMP288 will be radio-labeled with 111In (imaging) for the first injection and then 90Y (therapy) for the 2 subsequent injections.

Enrollment: 7 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

1. Metastatic colorectal cancer and failure to standard therapies (5-fluorouracil, irinotecan, oxaliplatin, anti-vascular endothelium growth factor, anti-epidermal growth factors in patients with RAS wild type tumors). A previous line with regorafenib is not required.
2. Elevated CEA serum level or proved CEA expression in tumor tissue
3. ≥ 18 years of age,
4. Given signed, written informed consent
5. Existence of at least one measurable tumor lesion by CT or MRI at the time of treatment, but no single lesion ≥ 8 cm in diameter.
6. At least 4 weeks recovery period after any major surgery, radiation, or chemotherapy, and total recovery from any acute toxicities associated with these prior treatments.
7. Life expectancy ≥ 3 months, Karnofsky performance status of ≥ 70%
8. Adequate hematology and renal function and hepatic function
9. Patients of childbearing potential must be willing to practice birth control during the study until at least 12 weeks after treatment, and women of childbearing potential must have a negative serum pregnancy test to enter the study

Exclusion Criteria :

1. Known central nervous system metastatic disease

2. > 25% bone marrow involvement

3. CEA plasma levels >2,000 ng/mL

4. Patients with successfully treated non-melanoma skin cancer or carcinoma in situ of the cervix are eligible, while patients with other prior malignancies must have had at least a 3-year disease-free interval.

5. HIV positive, hepatitis B-antigen positive, or hepatitis C positive patients

6. Known autoimmune disease,

7. Known history of unstable angina, myocardial infarction, or congestive heart failure present within 6 months or clinically significant cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy, no known history of clinical significant, active chronic obstructive pulmonary disease, or other moderate to severe chronic respiratory illness present within 6 months

8. Infection requiring intravenous antibiotic use within 1 week before inclusion,

9. Corticosteroids are not allowed within 2 weeks of study entry nor during the study except low doses (i.e., 20 mg/day of prednisone or equivalent) to treat nausea or other illness such as rheumatoid arthritis.

10. Patients who received a treatment containing a nitrosourea compound will not be enrolled for at least 6 weeks after the end of that treatment.

11. Known hypersensitivity to murine antibodies or proteins

12. Immunization against TF2 for patients who has already received injection of TF2

13. Adult patient unable to give informed consent because of intellectual impairment.

14. Adult patient protected by the French law

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

7 participants in 1 patient group

several cohorts

Experimental group

Description:

All patients will receive 3 injections of TF2 (the first: 14 mg/m², the second and the third:75 mg/m²). One day after each injection of TF2, the patient will receive a radiolabelled peptide (IMP-288) with Yttrium for therapeutic injectionThe First cohort will receive 555 MBq/m2 X 2 of 90-Y-IMP-288.: All patient will receive 180 MBq of 111-In-IMP-288 for dosimetry analysis

Treatment:

Drug: 90-Y-IMP-288

Drug: 111-In-IMP-288

Drug: Antibody TF2